Glucagon-Like Peptide 1
- Glucagon-Like Peptide 1
- Accession Number
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
Drug Drug Description Vildagliptin A once-daily dipeptidyl peptidase 4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. Exenatide A GLP-1 agonist used in the management of type 2 diabetes mellitus. Liraglutide A GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes. Avexitide Avexitide is under investigation in clinical trial NCT02996812 (Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia).
- Drugs & Drug Targets
Drug Target Type Vildagliptin Dipeptidyl peptidase 4 target Exenatide Glucagon-like peptide 1 receptor target Exenatide Serum albumin carrier Exenatide Dipeptidyl peptidase 4 enzyme Liraglutide Glucagon-like peptide 1 receptor target Liraglutide Dipeptidyl peptidase 4 enzyme Liraglutide Neprilysin enzyme Liraglutide Serum albumin carrier